Excalipoint Therapeutics has announced an oversubscribed $68.7m seed financing round to support advancement of its proprietary technology platforms and pipeline of differentiated T-cell engager programmes.
The seed round represents one of the largest early-stage financings for a Chinese biotechnology company.
Excalipoint was co-founded by Lei Fang, co-founder, chairman and chief executive officer, and Jielun Zhu, co-founder, chief financial officer and chief business officer. Fang previously held leadership roles at Lepu Biopharma and I-Mab Biopharma, while Zhu brings more than 20 years of healthcare and capital markets experience, including leadership roles at I-Mab Biopharma, Fapon Group, and Jefferies.
The new funding will support advancement of Excalipoint’s proprietary platforms – TOPAbody, T-Cell Immune Shield, and TCE Probody – as well as a pipeline of six differentiated programmes with first- or best-in-class potential. These are designed to improve the efficacy, safety, and durability of T-cell immunotherapies for solid tumours and other difficult-to-treat cancers.
Excalipoint’s next-generation platforms are designed to overcome key biological barriers that have historically limited T-cell engager therapies, including converting “cold” tumours into “hot” tumours, addressing the tumour microenvironment, and enabling targeting of difficult-to-drug tumour antigens. Supported by these platforms, the company is building a diversified pipeline to reduce single-asset risk and drive value through strategic partnerships and out-licensing.
Excalipoint’s pipeline includes the following programmes:
EXP011 (CTM012) – A tri-specific antibody targeting DLL3, CD3, and 4-1BB, being developed for small cell lung cancer, neuroendocrine tumours, and other DLL3-expressing malignancies. The company initiated a phase I/II clinical trial with the first patient dosed in October 2025.
EXP012 (CTM013) – A tri-specific antibody targeting CDH17, CD3, and 4-1BB, being developed to treat colorectal, gastric, and pancreatic cancers.
EXP016 – A tri-specific antibody leveraging the TOPAbody platform designed to target solid tumours with high unmet medical need.
EXP017 – A multi-specific antibody developed using the Immune Shield platform aimed at addressing key limitations of the tumour microenvironment.
EP101 – A molecule enhanced with the Pro-TCE platform technology designed to enable targeting of challenging tumour-associated antigens.
EXP015 – A tri-specific antibody derived from the TOPAbody platform targeting IgG-associated diseases in immunology.
“Excalipoint is developing a proprietary pipeline and three powerful technology platforms to position our company as a true innovation powerhouse and developer of T-cell engagers,” Fang said.
“By combining science and capital with China’s clinical development efficiency and access to large patient populations, we can rapidly generate clinical data while advancing a pipeline of differentiated therapies. Our progress reflects the strength and maturity of China’s biotech ecosystem, which has become an essential part of the global innovation value chain. The strong support from top-tier investors validates both our science and this new approach to building a globally competitive biotechnology company.”
“Our successful launch and backing from top-tier investors highlight Excalipoint’s strong growth potential. In just six months, we added two technology platforms and expanded our pipeline to six differentiated programmes,” Zhu said.
“Built on a NewCo model, we are combining disciplined capital deployment, focused execution, and cross-border partnerships to efficiently translate our science into clinical progress and long-term value.”
Founded under a China NewCo model that integrates experienced founders, pipeline assets, and venture capital to accelerate drug development, Excalipoint has evolved into a multi-platform clinical-stage biotechnology company focused on next-generation T-cell engager therapeutics.